share_log

CVS Health | 10-Q: Q2 2024 Earnings Report

CVS Health | 10-Q: Q2 2024 Earnings Report

西維斯健康 | 10-Q:2024財年二季報
美股SEC公告 ·  08/07 18:41
牛牛AI助理已提取核心訊息
CVS Health reported a decrease in operating income for the quarter ended June 30, 2024, with a GAAP measure of $3.045 billion compared to $3.234 billion in the same period in 2023. Adjusted operating income also saw a decline, from $4.481 billion in 2023 to $3.744 billion in 2024. The company's financial performance was impacted by various factors, including amortization of intangible assets, net realized capital losses, and acquisition-related costs. Despite these challenges, CVS Health continued to develop its business, completing acquisitions of Signify Health and Oak Street Health, and launching Cordavis, a subsidiary focused on biosimilar products. Looking ahead, CVS Health anticipates elevated Medicare Advantage plan utilization and medical cost pressures in its Medicaid business. The company expects growth in its new business ventures and aims to mitigate the impact of market dynamics and regulatory changes on its PBM activities. CVS Health's future plans include leveraging its integrated model to expand into personalized, technology-driven care delivery and health services, aiming to improve access to quality care, health outcomes, and reduce healthcare costs.
CVS Health reported a decrease in operating income for the quarter ended June 30, 2024, with a GAAP measure of $3.045 billion compared to $3.234 billion in the same period in 2023. Adjusted operating income also saw a decline, from $4.481 billion in 2023 to $3.744 billion in 2024. The company's financial performance was impacted by various factors, including amortization of intangible assets, net realized capital losses, and acquisition-related costs. Despite these challenges, CVS Health continued to develop its business, completing acquisitions of Signify Health and Oak Street Health, and launching Cordavis, a subsidiary focused on biosimilar products. Looking ahead, CVS Health anticipates elevated Medicare Advantage plan utilization and medical cost pressures in its Medicaid business. The company expects growth in its new business ventures and aims to mitigate the impact of market dynamics and regulatory changes on its PBM activities. CVS Health's future plans include leveraging its integrated model to expand into personalized, technology-driven care delivery and health services, aiming to improve access to quality care, health outcomes, and reduce healthcare costs.
2024年6月30日結束的季度,西維斯健康的營業收入出現下滑,按照美國通用會計準則的計算方法爲304.5億美元,相比2023年同期的323.4億美元有所下降。調整後的營業收入也有所下降,從2023年的448.1億美元下降到2024年的374.4億美元。公司的財務表現受到多種因素的影響,包括無形資產的攤銷、淨實現資本損失和收購相關成本等。儘管面臨這些挑戰,西維斯健康仍在拓展業務,完成了對Signify Health和Oak Street Health的收購,並推出了Cordavis,這是一個專注於仿製產品的子公司。展望未來,西維斯健康預計Medicare Advantage計劃的利用率升高,醫療成本在其醫療援助業務中面臨壓力。公司預計其新業務將實現增長,並旨在減輕市場動態和監管變化對其處方藥管理活動的影響。西維斯健康未來的計劃包括利用其整體模式擴展個性化、科技驅動的護理交付和健康服務,旨在改善醫療保健的質量與結果並降低醫療費用。
2024年6月30日結束的季度,西維斯健康的營業收入出現下滑,按照美國通用會計準則的計算方法爲304.5億美元,相比2023年同期的323.4億美元有所下降。調整後的營業收入也有所下降,從2023年的448.1億美元下降到2024年的374.4億美元。公司的財務表現受到多種因素的影響,包括無形資產的攤銷、淨實現資本損失和收購相關成本等。儘管面臨這些挑戰,西維斯健康仍在拓展業務,完成了對Signify Health和Oak Street Health的收購,並推出了Cordavis,這是一個專注於仿製產品的子公司。展望未來,西維斯健康預計Medicare Advantage計劃的利用率升高,醫療成本在其醫療援助業務中面臨壓力。公司預計其新業務將實現增長,並旨在減輕市場動態和監管變化對其處方藥管理活動的影響。西維斯健康未來的計劃包括利用其整體模式擴展個性化、科技驅動的護理交付和健康服務,旨在改善醫療保健的質量與結果並降低醫療費用。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。